Zenas BioPharma (NASDAQ:ZBIO – Get Free Report) and Pharming Group (NASDAQ:PHAR – Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, profitability, analyst recommendations and institutional ownership.
Institutional & Insider Ownership
0.0% of Pharming Group shares are held by institutional investors. 22.0% of Zenas BioPharma shares are held by company insiders. Comparatively, 2.1% of Pharming Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Analyst Recommendations
This is a breakdown of recent ratings and recommmendations for Zenas BioPharma and Pharming Group, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Zenas BioPharma | 1 | 2 | 6 | 0 | 2.56 |
| Pharming Group | 2 | 0 | 3 | 0 | 2.20 |
Valuation and Earnings
This table compares Zenas BioPharma and Pharming Group”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Zenas BioPharma | $10.00 million | 203.82 | -$377.74 million | ($8.99) | -3.48 |
| Pharming Group | $366.48 million | 2.26 | $2.85 million | $0.12 | 97.50 |
Pharming Group has higher revenue and earnings than Zenas BioPharma. Zenas BioPharma is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Zenas BioPharma and Pharming Group’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Zenas BioPharma | N/A | -122.45% | -58.04% |
| Pharming Group | 2.51% | 3.40% | 1.90% |
Risk & Volatility
Zenas BioPharma has a beta of -1.03, meaning that its share price is 203% less volatile than the S&P 500. Comparatively, Pharming Group has a beta of -0.01, meaning that its share price is 101% less volatile than the S&P 500.
Summary
Pharming Group beats Zenas BioPharma on 10 of the 14 factors compared between the two stocks.
About Zenas BioPharma
Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.
About Pharming Group
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
Receive News & Ratings for Zenas BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zenas BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
